… levels of inflammatory cytokines might be involved in the development of organ dysfunction
in COVID-19. Here, we can present a case of cytokine release syndrome induced by SARS–…

… (CRS) is a systemic inflammatory disease … by COVID-19 infection during treatment with
nivolumab and ipilimumab. Fever is a common event in cancer patients, especially in COVID-19-…

… patients with COVID-19 presenting cytokine release syndrome, thus … IL-6 blockade is
considered a therapeutic target to control cytokine release syndrome (CRS) related to COVID-19…

… subgroup of patients with severe COVID-19 might have a cytokine release syndrome. Such
patients have high levels of pro-inflammatory cytokines and chemokines that are associated …

… in patients with cytokine release syndrome was 575 pg/mL; the difference between mean
IL-8 concentration in patients with cytokine release syndrome versus COVID-19 was not …

… cytokine release syndrome (CRS) and mortality in patients with acute severe respiratory
syndrome coronavirus 2 (… the severity of coronavirus disease 2019 (COVID-19) via endogenous …

… cytokine interaction network and identify that four cytokines play … “cytokine” to summarize
the cytokines and pathways involved in CRS-related organ damage. Finally, we took “COVID-19…

… This cytokine release syndrome (CRS) may occur in up to 70% of patients depending on
conditioning therapy and cell construct, with ICU admission rates up to 13% [[36], [37], [38]]. …

… in COVID-19 including compromised immunity, worsening coagulopathy, and depletion
of blood bank resources [18]. The cytokine release syndrome is … 20% of COVID-19 cases [19]. …

… Moreover, tocilizumab has been shown to be effective against cytokine release syndrome
resulting from CAR-T cell infusion against B cell acute lymphoblastic leukemia. Blocking anti-…